Abstract

Cell kinetics have been shown to be an important predictor of clinical evolution of operated breast cancer. We established a method for the estimation of the proliferative activity of tumour cells obtained by fine needle sampling without aspiration (FNS), using simultaneously S-phase fractions (SPF) measured on DNA histograms and 5-bromodeoxyuridine (BrdU) labelling index (BLI) measured by flow cytometry. Biparametric BrdU/DNA flow cytometry could be performed in 122 of 189 (65%) consecutive patients. The mean BLI of the cytologically malignant FNS (118) was of 3.0 and the median of 2.2%. One hundred and forty-eight DNA histograms (78%) were suitable for SPF analysis, of which 141 presented malignant cells, showing a mean of 4.5 and a median of 3.5%, comparable to BLIs. These results were obtained from fluorescence peak area histograms with doublet discrimination and background subtraction allowing the measurements of SPFs as low as 0.4%. An excellent correlation was thus observed between BLIs and SPFs, for the 94 cases for which both results were available (r = 0.85). Infrequent discordances (9%) were noted with SPFs considerably higher than BLIs. Seven patients had three consecutive FNS of their tumour at weekly intervals before treatment. Some variability in the proportions of multiple subpopulations of tumour cells was observed on the DNA histograms. In contrast, proliferation indices (SPF or BLI) were reproducible, suggesting homogeneous growth rates. We conclude that an estimation of the proliferative activity of breast tumours at any stage of the disease is possible routinely by SPF and/or BLI analysis of FNS. At least one quantitative proliferation index could be obtained for 91% of patients.

Highlights

  • In a prospective study of feasibility, we developed complementary methods for assaying S-phase fractions (SPF) and BrdU labelling index (BLI) in vitro on the same tumour samples

  • All were diploid with low SPFs (0.7-2.0%) and BLI (0.3-1.1%)

  • SPFs could be computed in 141 cases (80%)

Read more

Summary

Introduction

In a prospective study of feasibility, we developed complementary methods for assaying SPF and BrdU labelling index (BLI) in vitro on the same tumour samples. The substitution of 5-bromodeoxyuridine (BrdU) to 3H-thymidine has been proposed as a more convenient method of measuring DNA synthesis, due to the instant immunofluorimetric detection (Dolbeare et al, 1983; Schutte et al, 1987). Tumour cells were obtained directly from the patients by fine needle sampling without aspiration.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call